Ann Dermatol.  2017 Aug;29(4):491-492. 10.5021/ad.2017.29.4.491.

A Case of Nail Psoriasis Improved by Treatment with Golimumab in a Psoriatic Arthritis Patient

• Jung SY

• KMID: 2388951
• DOI: http://doi.org/10.5021/ad.2017.29.4.491

Abstract

No abstract available.

MeSH Terms

Arthritis, Psoriatic*
Humans
Psoriasis*

Figure

• 

  Fig. 1 (A) Erythematous patch, swelling of distal interphalangeal joints with oil spots and nail plate crumbling on the right second and fourth fingers, and left thumb. (B) Improvement with respect to nail psoriasis after treatment with golimumab for 24 months.

Reference

1. Radtke MA, Beikert FC, Augustin M. Nail psoriasis-a treatment challenge. J Dtsch Dermatol Ges. 2013; 11:203–219.

2. Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007; 57:1–27.

3. Garg A, Gladman D. Recognizing psoriatic arthritis in the dermatology clinic. J Am Acad Dermatol. 2010; 63:733–748.

4. Byun SY, Kim BR, Choi JW, Youn SW. Severe nail fold psoriasis extending from nail psoriasis resolved with ustekinumab: suggestion of a cytokine overflow theory in the nail unit. Ann Dermatol. 2016; 28:94–97.

5. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009; 60:976–986.